China Manufacturing Landscape for Mitomycin C (CAS 50-07-7)
Mitomycin C remains one of the most clinically important antineoplastic antibiotics, used in oncology for bladder, gastric, and pancreatic cancers as well as in ophthalmic surgery. China hosts several of the world’s most experienced Mitomycin C producers, and our production facility in Zhejiang Province operates one of the most advanced fermentation and purification platforms for this critical oncology API. We supply directly to sterile injectable formulation manufacturers worldwide, providing pharmaceutical-grade Mitomycin C with the stringent quality profile required for parenteral use.
The manufacturing complexity of Mitomycin C — a fermentation-derived compound requiring careful handling due to its cytotoxic, mutagenic, and light-sensitive nature — makes manufacturer selection a critical decision for formulators. Our facility’s dedicated containment infrastructure and two decades of production experience provide the safety and quality assurance that oncology drug manufacturers demand.
Manufacturing Process & Facility
Our Mitomycin C production begins with controlled fermentation of Streptomyces caespitosus under optimized nutrient and aeration conditions. The fermentation broth undergoes solvent extraction, column chromatography, and repeated crystallization to achieve the exceptional purity levels required for injectable applications. All operations involving the isolated compound are conducted under strict containment protocols with occupational exposure limits (OEL) below 0.1 μg/m³.
Facility capabilities:
- Dedicated high-containment production suites with isolator technology for cytotoxic API handling
- Fermentation vessels from 5,000L to 20,000L with advanced bioprocess control
- Negative-pressure cleanroom environments with HEPA-filtered air handling
- Dedicated analytical laboratory equipped for potency, purity, and sterility-related testing
- Annual production capacity: 500 kg of pharmaceutical-grade Mitomycin C
- Validated decontamination and waste inactivation systems for cytotoxic materials
Our high-containment infrastructure represents a significant capital investment that serves as a barrier to entry for less specialized manufacturers, ensuring supply reliability from qualified sources.
Quality Standards & Multi-Pharmacopeial Compliance
Our Mitomycin C API meets USP, EP, and JP injectable-grade specifications:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | Blue-violet crystalline powder | Visual |
| Identification | Positive by UV, IR, HPLC | UV/IR/HPLC |
| Assay (anhydrous basis) | 95.0–102.0% | HPLC |
| Related Substances (total) | ≤3.0% | HPLC |
| Any Single Impurity | ≤1.0% | HPLC |
| Water Content | ≤1.5% | Karl Fischer |
| Bacterial Endotoxins | ≤0.25 EU/mg | LAL (kinetic turbidimetric) |
| Bioburden | ≤10 CFU/g | Membrane filtration |
| Residual Solvents | Meets ICH Q3C | GC-HS |
| Elemental Impurities | Meets ICH Q3D (parenteral) | ICP-MS |
Regulatory Documentation
Our complete Mitomycin C regulatory dossier supports customer registrations for injectable products:
- US FDA Drug Master File (Type II) — active, with successful FDA pre-approval inspection history
- EU CEP (Certificate of Suitability) — granted
- Japan PMDA DMF filed
- China NMPA registration for cytotoxic API production
- Complete process validation for three consecutive batches at commercial scale
- ICH Q1A/Q1B stability and photostability studies with 36-month data
- Occupational health and safety documentation including OEL determination studies
- Detailed containment validation reports
We provide Letters of Authorization for DMF cross-reference within 48 hours of request, expediting customer regulatory submissions.
Packaging & Logistics
Mitomycin C packaging reflects the compound’s cytotoxic nature and photosensitivity:
- Primary: Amber glass bottles, nitrogen-flushed, with PTFE-lined closures
- Secondary: Cytotoxic-labeled, tamper-evident outer containers (10g, 50g, 100g, 500g)
- Tertiary: UN-certified dangerous goods packaging per IATA/IMDG regulations
- Storage: 2-8°C, protected from light; cold-chain shipping mandatory
- Shelf life: 24 months under recommended conditions
All shipments are classified as dangerous goods and handled by specialized pharmaceutical/cytotoxic logistics providers. We coordinate complete export documentation including safety data sheets, dangerous goods declarations, and customs clearance paperwork.
Competitive Pricing & Supply Reliability
Mitomycin C manufacturing requires specialized facilities and expertise that limit the global supplier base. Our competitive advantages include:
- Proprietary high-yield Streptomyces strains reducing per-unit fermentation costs
- Optimized purification process achieving high recovery rates
- Dedicated facility with no campaign changeover costs for cytotoxic production
- Strategic raw material sourcing with qualified backup suppliers
Given the critical nature of Mitomycin C in oncology treatment, we maintain safety stock inventory and offer priority supply agreements to ensure uninterrupted supply for essential medicines. Contact our oncology API team for pricing, technical documentation, and supply agreement discussions.